Pharmacokinetics, adverse effects and effects on thermal nociception following administration of three doses of codeine to horses.
Authors: Knych Heather K, Stucker Kristen, Gretler Sophie R, Kass Philip H, McKemie Daniel S
Journal: BMC veterinary research
Summary
# Editorial Summary: Codeine as an Alternative Analgesic in Equine Medicine Morphine is an effective analgesic in horses but causes problematic dose-dependent neuroexcitation; codeine, which metabolises to morphine and its active metabolite morphine-6-glucuronide, had shown promise in preliminary work as producing comparable plasma concentrations without unwanted excitatory effects. Knych and colleagues administered three doses of oral codeine (0.3, 0.6 and 1.2 mg/kg) alongside intravenous morphine (0.2 mg/kg) and saline control to seven horses in a crossover design, measuring plasma metabolite concentrations via liquid chromatography-mass spectrometry and evaluating behavioural responses, locomotor activity, heart rate, gastrointestinal sounds and thermal nociceptive thresholds over 72 hours. The 0.6 mg/kg dose generated morphine and M6G concentrations comparable to those from morphine administration, whilst the 1.2 mg/kg dose produced higher metabolite concentrations, yet codeine administration produced neither the neuroexcitation nor adverse behavioural changes observed with morphine—a significant finding given morphine's clinical limitations in equine practice. Thermal nociception testing demonstrated analgesic effects, though the practical analgesia duration and potency relative to morphine warrant further investigation. Codeine may offer equine practitioners a more manageable oral analgesic option, particularly where morphine's excitatory side-effects are problematic, though dose optimisation and assessment in clinical pain models remain necessary before widespread adoption.
Read the full abstract on PubMed
Practical Takeaways
- •Oral codeine at 0.6 mg/kg may offer an alternative analgesic option for horses that avoids the neuroexcitation problems associated with morphine administration.
- •This pharmacokinetic profile suggests codeine could be useful for practitioners seeking safer opioid analgesia, though clinical efficacy data and safety monitoring protocols require further validation.
- •The conversion of codeine to morphine and its active metabolites in horses differs from morphine administration alone, potentially reducing undesirable behavioral and locomotor side effects.
Key Findings
- •Oral codeine at 0.6 mg/kg produced morphine and M6G concentrations comparable to clinically effective IV morphine doses without morphine's neuroexcitatory adverse effects in horses.
- •Codeine demonstrated dose-dependent pharmacokinetics with measurable morphine and M6G metabolites at all three doses tested (0.3, 0.6, 1.2 mg/kg).
- •Thermal nociceptive thresholds and behavioral responses were evaluated to assess analgesic efficacy and safety compared to IV morphine control.